Feedback
Settings

Settings

Goto Application

83,884 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NYHBQMYGNKIUIF-UUOKFMHZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,389
1.WO/2026/020120INCREASING CAS9 GENOME EDITING FIDELITY THROUGH ATTENUATION OF GUIDE RNA WATSON-CRICK BASE PAIRING POTENTIAL
WO - 22.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/038284 Applicant UNIVERSITY OF MASSACHUSETTS Inventor WOLFE, Scot
Systems including a nucleic acid programmable DNA binding protein and a guide RNA, having reduced off-target activity, are described. Off-target activity is reduced by attenuating the base pairing potential of a spacer sequence of the guide RNA with its target sequence by selective base substitutions in the spacer sequence.
2.WO/2026/017174PRECURSOR RNA MOLECULES AND METHODS FOR PRODUCING CIRCULAR RNAS
WO - 22.01.2026
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/CN2025/109554 Applicant RIBOX THERAPEUTICS HK LIMITED Inventor LI, Siqi
Provided are engineered precursor RNA molecules, vectors as well as methods for producing circular RNA molecules, and circular RNA molecules thus produced and a composition comprising the same.
3.WO/2026/018824NUCLEIC ACID DRUG AND USE THEREOF
WO - 22.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/JP2025/025230 Applicant VERITAS IN SILICO INC. Inventor NAKAMURA Shingo
The purpose of the present invention is to provide a drug for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).　The present inventors identified oligonucleotides that inhibit MP-13 mRNA, which is a splicing variant (TDPsv) of TDP-43. Use of these oligonucleotides can reduce the amount of MP-13 mRNA and suppress protein expression. These oligonucleotides can be useful for the treatment or prevention of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
4.WO/2026/018181IMMUNOGENIC COMPOSITIONS AND USES THEREOF
WO - 22.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/057203 Applicant PFIZER INC. Inventor HUANG, Bridget Yih Jiin
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
5.WO/2026/019922USES OF LIPID NANOPARTICLES CONTAINING CRISPR-ASSOCIATED PROTEINS (CAS) AND GUIDE RNA IN MANAGING VIRAL INFECTIONS
WO - 22.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/037913 Applicant EMORY UNIVERSITY Inventor SANTANGELO, Philip J.
Disclosed herein are compositions and methods for managing viral infections. In certain embodiments, this disclosure relates to compositions that specifically cleave target sequences in viruses, such as dengue virus. Such compositions include lipid nanoparticles containing nucleic acids encoding a Cas guide-RNA associated endonuclease, with a guide sequence of a viral target sequence. In certain embodiments, contemplated methods include treating a viral infection by administering lipid nanoparticles (LNPs) comprising mRNA encoding Cas13a and a guide RNA or multiple guide RNAs that target regions of a dengue genome or other viral genome.
6.WO/2026/016998MRNA MOLECULE ENCODING BISPECIFIC ANTIBODY AGAINST GPC3 AND CD3
WO - 22.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2025/108363 Applicant BEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO., LTD. Inventor LV, Yao
The present invention relates to the field of biomedicine, and in particular to the field of RNA drugs. Specifically, the present invention provides an mRNA molecule encoding a bispecific antibody against GPC3 and CD3 and a lipid nanoparticle (LNP) comprising the mRNA molecule. The present invention also provides a medical use of the mRNA molecule and the LNP.
7.WO/2026/018213A BROADLY PROTECTIVE MOSAIC VACCINE AGAINST HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUSES
WO - 22.01.2026
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No PCT/IB2025/057302 Applicant VAXTHERA SAS Inventor OSORIO, Jorge E.
Disclosed herein are mosaic avian influenza (e.g., H5N1) proteins or fragments thereof. Also disclosed herein are nucleic acid constructs, avian influenza vaccine vectors, avian influenza vaccines, host cells, pharmaceutical compositions, and kits comprising the mosaic avian influenza (e.g., H5N1) proteins or fragments thereof. Also disclosed herein are methods of eliciting an immune response in a subject and methods of preventing, reducing the incidence of, attenuating, or treating avian influenza infection in a subject in need thereof.
8.WO/2026/019998VACCINES FOR KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS
WO - 22.01.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/038046 Applicant THE CLEVELAND CLINIC FOUNDATION Inventor JUNG, Jae
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
9.WO/2026/017841CELLULAR MEMBRANE-DERIVED NANOCARRIERS FOR BRAIN DELIVERY
WO - 22.01.2026
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
 Appl.No PCT/EP2025/070615 Applicant UNIVERSIDADE DE SANTIAGO DE COMPOSTELA Inventor POLO TOBAJAS, Ester
The present invention provides a homogeneous population of cell-derived nanoparticles, comprising (a) a surface, wherein the surface comprises a.1) a portion of an isolated cellular membrane and a.2) at least one fusion protein comprising RVG peptide fused to lysosome-associated membrane protein 2b, and (b) at least one cargo of interest.
10.WO/2026/019267ENGINEERED CAS POLYPEPTIDES HAVING IMPROVED EDITING PERFORMANCE AND USES THEREOF
WO - 22.01.2026
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/KR2025/010508 Applicant GENKORE INC. Inventor KIM, Yong-Sam
The present invention relates to: an engineered Cas polypeptide having improved gene editing performance; and uses thereof in gene editing.
# -